Sponsor:
Abramson Cancer Center at Penn Medicine
Code:
NCT07278986
Conditions
Endometrial Cancer
Near Infrared Fluorescence Imaging
CYTALUX (Pafolacianine) Injection
Planned Diagnostic Laparoscopies
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CYTALUX™ (pafolacianine)
1788 4K Camera System with Advanced Imaging Modality
Brief summary:
Conditions
Endometrial Cancer
Near Infrared Fluorescence Imaging
CYTALUX (Pafolacianine) Injection
Planned Diagnostic Laparoscopies
Study ID
NCT07278986
Start date
Oct 18, 2025
Status verified date
Dec, 2025
Completion date
Feb, 2029
Anticipated
Primary completion date
Oct, 2027
Anticipated
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
10 participants
Anticipated
Intervention Model
Single group
Primary purpose
Diagnostic
Arms
other: CYTALUX™ (pafolacianine) injection and standard care laparoscopic evaluation of disease.
Interventions
CYTALUX™ (pafolacianine)
1788 4K Camera System with Advanced Imaging Modality
Primary outcome measure
Central contacts
Locations
Abramson Cancer Center at Penn Medicine
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contacts
Principal Investigator:
Janos L Tanyi, MD, PhD
University of Pennsylvania Gynecologic Oncology Department
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contacts
Principal Investigator:
Janos L Tanyi, MD, PhD
Sponsor
Abramson Cancer Center at Penn Medicine
Last update posted
Dec 12, 2025
Last verified
Dec, 2025
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2025-12-12.